To study the relation between plasma atrial natriuretic factor (ANF) and cardiac pressures, we measured plasma ANF in 24 patients with mitral stenosis 30 minutes before and 20 minutes after balloon mitral valvulotomy. All patients were without physical signs of congestive heart failure. Normal sinus rhythm was present in 15 (group 1), whereas the other nine (group 2) had permanent atrial fibrillation. There were no significant differences between groups for basal mean pressures in right atrium (RA), left atrium (LA), and pulmonary artery (PA). Valvulotomy resulted in a fall in both groups (p<0.001) in LA and PA mean pressures, whereas heart rate, cardiac index, and RA and aorta (AO) pressures did not change significantly. Basal (cGMP) in LA was correlated (p<0.01) with PA ANF in group 1, and LA cGMP (10.0± 1.2 and 9.1 1.8 pmollml in groups 1 and 2, respectively) was higher (p<0.05) than PA cGMP (9.1 1.0 and 8.0 1.5 pmollml in groups 1 and 2, respectively) before valvulotomy, which suggests the presence of ANF receptors in the pulmonary circulation. Taken together, these results indicate that in patients in sinus rhythm with mitral stenosis, there is an increase in ANF secretion depending on LA pressure. ANF secretion is also high in patients with mitral stenosis and atrial fibrillation but does not respond appropriately to changes in LA pressure. cGMP production in the lungs is related to ANF secretion in patients with sinus rhythm, whereas it seems to be independent in those with atrial fibrillation. (Circution 1988;78:276-285) It has been clearly established that secretion of atrial natriuretic factor (ANF) was regulated by the atrial stretch,' which essentially depends on the pressures in both atria. Most studies in humans have been performed in patients with cardiac diseases who are undergoing right heart catheterization.2-6 These studies provided no infor- From 
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The present study provides information on these different points and, in particular, demonstrates that ANF response to changes in left atrial pressure is inappropriate in patients with atrial fibrillation.
Patients and Methods Patients
Thirty-four patients with mitral stenosis were treated by balloon mitral valvulotomy7 over a period of 4 months. They were divided into two groups. Group I included 15 patients (two men and 13 women) with normal sinus rhythm at the time of the study, without any history of atrial fibrillation, and who never had been treated with antiarrhythmic drugs. Group 2 included nine patients who had been in permanent atrial fibrillation for at least 6 months. The remaining 10 Essentially, we studied the correlation between plasma ANF in PA (y axis; pg/ml), which seems, in the present study, the best index of locally secreted ANF and LA pressure (x axis; mm Hg). Both parameters were significantly correlated before (y=30.6x-159; r=0.61, p<0.05) and after (y=22.4x+208; r=0.58, p<0.05) valvulotomy in group 1. On the contrary, no correlation was observed in group 2 either before or after valvulotomy (Figure 3) . The sites of blood collection, valvulotomy) analysis of variance. ANF plasma levels, as a whole, fell significantly (p<O.OO1) after valvulotomy in group 1, whereas they increased in group 2 (p<O.OS). We studied, in some patients (seven in group 1 and six in group 2), the effect of balloon occlusion of the mitral valve on plasma ANF in PA ( Figure 4 ). Plasma ANF increased significantly 1 minute after balloon occlusion in group 1 (p<0.01). There was also an increase in group 2, but it did not reach the level of significance. We could also measure plasma ANF in the peripheral venous blood 48 hours after mitral valvulotomy (Table 2) . In group 1, ANF levels at this time (97±22 pg/ml) were significantly (p<0.05) lower than 24 hours before valvulotomy (187 ± 31 pg/ml). In contrast, no difference was observed in patients of group 2 Correlation Between ANF Plasma Levels and cGMP Plasma Levels Twenty-four hours before catheterization, cGMP levels in the peripheral venous blood were not significantly different in groups 1 (7.50 ± 1.26 pmol/ml) and 2 (7.86+1.5 pmol/ml). These values were greater (p<0.05) than those measured under the same conditions (supine position) in a group of 11 healthy control subjects selected from the medical staf (4.31 + 0.37 pmollml). During catheterization, plasma cGMP levels varied with the site of blood collection in both groups of patients ( Figure  5 ). Before valvulotomy, plasma cGMP was significantly (p<O.05) greater in LA (10.03±1.21 and 9.09± 1.78 pmol/ml in groups 1 and 2, respectively) than in PA (9.08±1.01 and 8.01+1.55 pmol/ml, respectively). Therefore, it was possible to calculate a net addition of cGMP to the pulmonary circulation that was 10.5% and 13.5% in groups 1 and 2, respectively. Net addition (9.3%) was also found after valvulotomy in group 1 (10.14 ± 1.21 and 9.28±0.91 pmol/ml in LA and PA, respectively; p<0.05) but not in group 2. Plasma cGMP in AO (10.55±1.41 and 8.92±1.73 pmol/ml in groups 1 and 2, respectively) was higher than in RA (8.63 ± 0.79 and 6.51 ± 1.33 pmol/ml in groups 1 and 2, respectively) before mitral valvulotomy. This indicates that cGMP was cleared from the systemic circulation with extraction coefficients of 18.2% and 27.0% in groups 1 and 2, respectively. These differences between cGMP concentrations in AO and RA were not observed 30 minutes after mitral valvulotomy. There was no difference between cGMP plasma levels of either group regardless of the site (RA, PA, LA, or AO) or the time (20 minutes before or 30 minutes after valvulotomy) of blood collection.
Plasma cGMP in AO was also measured simultaneously with PA plasma ANF in a limited number of patients 1 minute after balloon occlusion ( Figure   4 ). Plasma cGMP increased significantly in both groups 1 11 who observed that plasma ANF in PA increased some minutes after valvulotomy and then decreased to levels lower than initial levels. Our present study first indicates that plasma ANF measured in the peripheral venous blood is seven to ten times greater in patients with severe mitral stenosis but without physical sign of congestive heart failure than in healthy control subjects. Plasma ANF levels were not significantly different in RA and the peripheral venous blood. The highest values were found in PA (488-+93 and 759±92 pg/ml in groups 1 and 2, FIGURE 6. Plots of plasma cyclic GMP (cGMP) in left atrium (LA) plotted against plasma ANF in pulmonary artery (PA) 30 minutes before balloon valvulotomy in two groups of patients with mitral stenosis. Group 1 (I) (n=14) includes patients with sinus rhythm and group 2 (IH) (n=9) includes those with atrial fibrillation. Regression line is shown only for data from group 1 (p<0.001). Correlation between both parameters was found not significant in group 2.
(pg/mno respectively). High values of ANF in PA of patients with mitral stenosis have been also observed by Waldman et all' and Yoshimi et a112 but with a greater dispersion (228-+±124 and 357+± 381 pg/ml, respectively) than in our present study. The high gradient of ANF concentrations between RA and PA indicates a net addition of ANF in the right heart. This confirms that ANF is not secreted directly from the atrial wall but through the coronary sinus.13 Plasma ANF in AO was significantly greater than that in RA regardless of the time of blood collection and the group of patients. The coefficient of extraction of ANF in the systemic circulation calculated from these data was 45-60%. This confirms that ANF is catabolized in the tissues, probably for the most part in the kidney.'3'14 Plasma ANF in LA was also lower than that in PA. But the coefficient of extraction of ANF in the pulmonary circulation only reached 6-12%. This indicates that plasma ANF is little destroyed during its passage through the lungs. An alternative possibility suggested by the finding of ANF in the walls of the pulmonary vessels15 is that ANF is both destroyed and produced in the pulmonary circulation.
It was possible in the present study to measure simultaneously plasma ANF and blood pressures in the different heart cavities and vessels. Essentially, we studied ANF concentration in PA because this parameter was considered to be the best index of ANF secretion. Moreover, we verified that plasma ANF in LA was highly correlated with ANF in PA regardless of the group of patients and the time of blood collection (r= 0.93-0.99; p<0.001). This indicates that variations of each value obey the same regulation. Plasma ANF in PA was correlated with mean blood pressure in LA in group 1 both before and after valvulotomy. The range of pressures studied was between 10 and 35 mm Hg (1.33 and 4.66 kPa). In contrast, no correlation was observed between plasma ANF in PA and RA pressure. Correlations between central plasma levels of ANF and hemodynamic data have previously been studied in humans. Bates et a116 found that RA pressure in patients with various cardiac diseases was the hemodynamic variable that best correlated with plasma ANF in the right ventricle (RV). Correlation of pulmonary arterial wedge pressure with RV plasma ANF was also significant in their study. Sato et a113 also observed in a series of 17 patients that plasma ANF in PA was significantly correlated with mean pulmonary arterial wedge pressure but, in contrast with Bates et al, they found no correlation of plasma ANF with mean RA pressure under control conditions-only after injection of contrast medium. Our study provides, for the first time, direct information on the relation between ANF secretion and pressure in LA in a homogeneous series of 15 4, 5 Although all patients of the group with atrial fibrillation were without physical signs of cardiac failure, mean cardiac index tended to be lower in this group. However, cardiac index does not seem to play an essential role in the results because it was not significantly correlated with the change in PA plasma ANF after balloon valvulotomy. In addition, PA plasma ANF was not significantly different in the 12 patients with the lowest cardiac indexes and in the 12 others with the highest cardiac indexes both before (p=0.11) and after (p=0.13) valvulotomy. Patients of group 2 were older than those of group 1. This may have played a role because plasma ANF increases progressively with age. 19 In fact, plasma ANF in PA was not significantly different when the population studied was separated into two groups including the 12 oldest and the 12 youngest patients, respectively, before (p= 0.52) as well as after (p = 0.14) balloon valvulotomy. Moreover, PA Plasma ANF may play a role in the pathophysiology of mitral stenosis. In response to elevated pressure in LA, ANF secretion is increased, which in turn results in an increased plasma cGMP in the pulmonary circulation. ANF, through cGMP, would diminish the vascular resistances in the lung capillaries and thus counteract the effect of the mitral stenosis on PA pressure. Such a hypothesis is in agreement with the beneficial effect of the infusion of ANF in patients with cardiac failure associated with the decrease of pulmonary capillary wedge pressure. 4, 26 
